Table of Content

1. Research Methodology


2. Introduction to PLK Targeted Therapy
2.1 Overview
2.2 Development & Evolution


3. PLK Targeted Therapy Clinical Approaches
3.1 Small Molecule Inhibitors
3.2 RNA Interference
3.3 Antisense Oligonucleotides
3.4 PROTAC Degraders


4. PLK Targeted Therapy Clinical Application by Indication
4.1 Cancer
4.1.1 Overview
4.1.2 Ongoing Research & Development
4.2 Microbial Infections
4.3 Autoimmune Diseases


5. PLK Targeted Therapy Combination Strategies
5.1 Combination with Chemotherapies
5.2 Combination with Immunotherapies
5.3 Combination with Targeted Therapies


6. PLK Targeted Therapies Market Overview
6.1 Current Market Trends
6.2 Future Commercialization Outlook


7. PLK Targeted Therapies Market Dynamics
7.1 Market Drivers & Opportunities
7.2 Market Challenges & Restraints



8. Global PLK Targeted Therapies Clinical Trials Overview
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Priority Status
8.6 Patient Segment


9. PLK Targeted Therapies Clinical Trials insight By Company, Country & Indication
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
9.6 Phase III


10. Competitive Landscape
10.1 Biogenera
10.2 Boehringer Ingelheim
10.3 Cardiff Oncology
10.4 Cyclacel Pharmaceutical
10.5 Korea United Pharm
10.6 ORIC Pharmaceuticals
10.7 Pdx Pharmaceuticals
10.8 Repare Therapeutics
10.9 SillaJen Biotherapeutics
10.10 Treadwell Therapeutics



List of Figures

Figure 2-1: Some Biological Functions of PLKs
Figure 2-2: PLK-Targeted Therapies - Chronology of Events

Figure 4-1: Rigosertib Early Phase 1 (NCT04177498) Study – Initiation & Completion Year
Figure 4-2: Rigosertib Phase 1/2a (NCT04263090) Study – Initiation & Completion Year
Figure 4-3: Rigosertib Phase 2 (NCT05764395) Study – Initiation & Completion Year
Figure 4-4: Onvansertib Phase 2 (NCT06106308) Study – Initiation & Completion Year
Figure 4-5: Onvansertib Phase 2 (NCT05450965) Study – Initiation & Completion Year
Figure 4-6: Onvansertib Phase 1 (NCT05549661) Study – Initiation & Completion Year
Figure 4-7: Ocifisertib Phase 1/2 (NCT04730258) Study – Initiation & Completion Year
Figure 4-8: Ocifisertib Phase 2 (NCT03624543) Study – Initiation & Completion Year
Figure 4-9: Ocifisertib Phase 1 (NCT03187288) Study – Initiation & Completion Year
Figure 4-10: RP-1664 Phase 1 (NCT06232408) Study – Initiation & Completion Year
Figure 4-11: Plogosertib Phase 1 (NCT05358379) Study – Initiation & Completion Year
Figure 4-12: BAL0891 Phase 1 (NCT05768932) Study – Initiation & Completion Year

Figure 6-1: PLK Targeted Therapies – Future Opportunities

Figure 7-1: PLK Targeted Therapies Market - Drivers & Opportunities
Figure 7-2: PLK Targeted Therapies Market - Challenges & Restraints

Figure 8-1: Global – PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
Figure 8-2: Global – PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
Figure 8-3: PLK Targeted Therapies Clinical Pipeline by Company (Numbers), 2024

Figure 8-4: Global - PLK Targeted Therapies Clinical Pipeline by Indication (Numbers), 2024
Figure 8-5: Global - PLK Targeted Therapies Clinical Pipeline by Fast Track Designation (Numbers), 2024
Figure 8-6: Global - PLK Targeted Therapies Clinical Pipeline by Patient Segment (Numbers), 2024
 

List of Tables

Table 5-1: PLK Inhibitor & Chemotherapy Combinations in Clinical Trials, April’2024